secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2026-09-09T14:12:04+00:00
Accession:  0001640334-26-001468
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria raises ~$5.9M via warrant exercise at $12.92/share; issues new warrants
-------------------------------------------------------------------------------

- 453,969 existing warrants exercised at reduced $12.92/share, gross proceeds ~$5.9M before fees.
- New Series A warrants (5-yr, $12.67) and Series B warrants (18-mo, $12.67) issued for 453,969 shares each.
- H.C. Wainwright acts as placement agent; fee 7% of gross proceeds plus 15,889 agent warrants at $16.15.
- CEO cites $2.6M Australian Tax Office rebate received; proceeds to fund 2027 operations and R&D.
- Closing expected Sept 9, 2026; resale registration statement to be filed within 30 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033426001468/0001640334-26-001468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033426001468/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-26-001468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer